Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16044
Title: Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
Austin Authors: Gupta, VB;Doecke, JD;Hone, E;Pedrini, S;Laws, Simon M;Thambisetty, M;Bush, AI;Rowe, Christopher C ;Villemagne, Victor L ;Ames, David;Masters, Colin L ;Macaulay, S Lance;Rembach, A;Rainey-Smith, Stephanie R;Martins, Ralph N;AIBL Research Group
Affiliation: School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia
School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Cooperative Research Centre for Mental Health, Melbourne, Australia
National Ageing Research Institute, Parkville, Australia
Unit of Clinical and Translational Neuroscience Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
CSIRO Health and Biosecurity, Brisbane, Australia
Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Australia
Oxidation Biology Unit, The Florey Institute, The University of Melbourne, Melbourne, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
CSIRO Food and Nutrition Flagship, Parkville, Australia
Issue Date: 22-Dec-2015
Publication information: Alzheimer's & Dementia (Amst) 2016; 3: 18-26
Abstract: INTRODUCTION: For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. METHODS: Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini-mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B-positron emission tomography), and total adjusted hippocampus volume. RESULTS: ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both "standardized uptake value ratio" (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1-42/Aβ1-40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18-month time points. DISCUSSION: Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16044
DOI: 10.1016/j.dadm.2015.12.001
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27239546
Type: Journal Article
Subjects: Apolipoprotein J
Biomarkers
Brain amyloid beta
Hippocampus volume
Plasma
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.